Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for Ascendis Pharma A (ASND) over the last 7 years, with Sep 2025 value amounting to $400.2 million.

  • Ascendis Pharma A's Total Non-Current Liabilities rose 3.34% to $400.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400.2 million, marking a year-over-year increase of 3.34%. This contributed to the annual value of $408.4 million for FY2024, which is 61.68% up from last year.
  • Per Ascendis Pharma A's latest filing, its Total Non-Current Liabilities stood at $400.2 million for Q3 2025, which was up 3.84% from $385.4 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Total Non-Current Liabilities high stood at $798.9 million for Q3 2023, and its period low was $108.0 million during Q1 2021.
  • In the last 3 years, Ascendis Pharma A's Total Non-Current Liabilities had a median value of $387.3 million in 2024 and averaged $435.1 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Total Non-Current Liabilities soared by 532.72% in 2022, and later crashed by 62.21% in 2023.
  • Ascendis Pharma A's Total Non-Current Liabilities (Quarterly) stood at $115.5 million in 2021, then skyrocketed by 478.88% to $668.4 million in 2022, then tumbled by 62.21% to $252.6 million in 2023, then soared by 59.63% to $403.2 million in 2024, then climbed by 3.34% to $400.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $400.2 million for Q3 2025, versus $385.4 million for Q2 2025 and $384.7 million for Q1 2025.